Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O’Brien(Royal Marsden NHS Foundation Trust), Solange Peters(University Hospital of Lausanne), Jong Seok Lee(Brigham and Women's Hospital), Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari), Rolf A. Stahel(International Breast Cancer Study Group), Martin Faehling(Klinikum Esslingen), Benjamin Besse(Institut Gustave Roussy), Kersti Oselin(North Estonia Medical Centre), Emilio Esteban(Hospital Universitario Central de Asturias), Masahiro Tsuboi(National Cancer Center Hospital East), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Ayman Samkari(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Nitish Jha(European Organisation for Research and Treatment of Cancer), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Urania Dafni(Frontier Science Foundation-Hellas), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Jing Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Murielle Mauer(Heidelberg University), Steven M. Keller(Merck & Co., Inc., Rahway, NJ, USA (United States)), Libor Havel(Chinese University of Hong Kong)
Cited by 738
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k